Marker Therapeutics, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Marker is a clinical-stage immuno-oncology company developing multiTAA-specific T-cell therapies, including MT-601 and MT-401-OTS. It has not generated revenue from product sales or licensing; reported revenue is grant income.
Financial highlights
| Metric | Q1 2024 | Q1 2023 / prior date |
|---|---|---|
| Grant revenue | $1.244 million | $1.234 million |
| Research and development | $2.575 million | $3.376 million |
| General and administrative | $1.218 million | $2.167 million |
| Operating loss | $2.549 million | $4.309 million |
| Net loss | $2.393 million, or $0.27 per share | $4.968 million, or $0.57 per share |
| Cash used in continuing operations | $3.837 million | $3.098 million |
| Cash and cash equivalents | $11.323 million | $15.111 million at Dec. 31, 2023 |
| Working capital | $11.788 million | $14.053 million at Dec. 31, 2023 |
There was no product-sales revenue. Grant income included approximately $0.8 million from CPRIT, $0.3 million from the FDA, and $0.2 million from NIH’s SBIR program. No debt is reported; total liabilities were $2.304 million, all current. Gross margin is not meaningful for this grant-funded clinical-stage business.
Changes and unusual items
- Operating expenses fell 32% year over year, and continuing-operations net loss narrowed by about 43%, primarily reflecting lower process-development, clinical-trial, headcount, and G&A costs. These savings were partly offset by $1.2 million of outsourced manufacturing and process-development expenses with Cell Ready.
- The prior-year comparison excludes manufacturing operations and related activity classified as discontinued operations after the June 2023 sale of assets to Cell Ready. Q1 2023 included a $0.743 million discontinued-operations loss; Q1 2024 had no discontinued-operations activity. The sale generated $19.0 million in cash consideration and an approximately $8.7 million gain in 2023.
- Cash declined by $3.788 million in Q1 2024. Financing provided $49,000, primarily from option exercises; there were no ATM share sales during the quarter.
Outlook, risks, and contingencies
- Management estimates that March 31 cash, together with available grant funding, will fund operating and capital requirements into Q4 2025. The filing says cash is sufficient for at least 12 months from issuance, but not to sustain operations beyond Q4 2025 without additional revenue or capital. The estimate depends on assumptions and could prove shorter.
- Management expects continued losses and substantial additional funding needs. Possible funding sources include equity or debt financing, grants, collaborations, and partnerships; equity issuance may dilute shareholders. Market volatility and macroeconomic conditions could impair access to capital.
- On February 22, 2024, Marker entered a three-year Master Services Agreement with Cell Ready, a CDMO owned by a director and shareholder. Cell Ready is providing research, development, and clinical manufacturing services; Marker incurred $1.2 million in Q1 expenses and paid $2.2 million against invoices. Additional work orders are expected. The related-party relationship and reliance on an external manufacturer warrant attention.
- Management reported that a City of Hope investigator described initial APOLLO study participants as tolerating the initial MT-601 dose level well and demonstrating durable objective responses. This is an investigator-reported clinical observation, not a filing-reported clinical outcome dataset.
- The company reported no material legal proceedings, no material changes to previously disclosed risk factors, and effective disclosure controls and procedures.
Important facts for investors to verify
- Whether the stated cash runway to Q4 2025 remains achievable as clinical plans, grant receipts, and spending evolve.
- Grant award balances, qualifying-cost requirements, receivables, and timing of future grant cash receipts.
- Clinical progress and supporting data for MT-401-OTS and MT-601, including the APOLLO observations and upcoming milestones.
- Cell Ready work-order costs, manufacturing performance, supply continuity, and safeguards around the related-party arrangement.
- Potential financing needs, ATM capacity and limitations, and the dilution or other terms of any future capital raise.